Abivax energized investor interest after reporting strong Phase 3 data for its oral ulcerative colitis candidate obefazimod, exceeding prior expectations. The company successfully launched a follow-on public offering on Nasdaq, raising $747.5 million, oversubscribed fivefold, to support ongoing clinical development and commercialization efforts. CEO Marc de Garidel highlighted the drug’s blockbuster potential. Shares rose dramatically in both US and European markets. Funding proceeds will advance obefazimod’s trials in ulcerative colitis and Crohn’s disease as well as broader corporate initiatives.